[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"microwave-ablation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:microwave-ablation":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,72,98,125,150],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640536","eus-guided-ablation-rfa-and-mwa-for-pancreatic-and-other-gastrointestinal-lesions-registry-100640536",false,"NCT07625189","EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions Registry","Prospective Observational Registry of EUS-Guided Ablation (RFA and MWA) for Pancreatic and Other Gastrointestinal Lesions","Inclusion Criteria:\n\n* Adults ≥ 18 years of age.\n* Diagnosis of a pancreatic premalignant lesion or malignancy, and other gastrointestinal or hepatobiliary lesion for which EUS-guided ablation is planned as part of standard clinical care.\n* At least one clinically identified target lesion for which RFA or MWA is performed.\n\nExclusion Criteria:\n\n* In the judgment of the treating clinician, inclusion in the registry would not be appropriate\n* The individual is expected to be unable to complete routine clinical follow-up.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","1 Year","OBSERVATIONAL","This is a single-center, investigator-initiated, prospective observational registry that will collect longitudinal clinical data on adult patients (≥18 years) undergoing endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) or microwave ablation (MWA) for pancreatic and other gastrointestinal\u002Fhepatobiliary lesions as part of routine clinical care. The registry will not alter standard-of-care management. Data will be abstracted from the medical record and routine clinical systems. Primary outcomes include change in target lesion size on clinically obtained imaging and overall survival following ablation. Secondary outcomes include changes in tumor biomarkers, adverse events, non-target lesion changes, and patient-reported symptoms.",[25,26,27,28,29],"RFA","Microwave Ablation","Pancreatic Lesion","Gastrointestinal Lesions","Ablation Techniques","RECRUITING","2026-05-30",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2026-03-10",{"date":38,"type":20},"2028-03",{"name":40,"class":41},"West Virginia University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100624056","microwave-ablation-for-treatment-of-vascular-malformations-efficacy-and-safety-100624056","NCT07404670","Microwave Ablation for Treatment of Vascular Malformations: Efficacy and Safety","A Multicenter, Prospective Study to Analyze the Efficacy and Safety of Microwave Ablation for the Treatment of Vascular Malformations","Inclusion Criteria:\n\n1. Patients with clinically diagnosed vascular malformations (venous malformations (VM) or arteriovenous malformations (AVM)) confirmed by MRI or ultrasound.\n2. Presence of symptomatic lesions (pain, swelling, functional impairment, or ulceration) that require treatment.\n3. Lesions that are amenable to microwave ablation based on preoperative clinical and imaging assessment.\n4. Ability to provide informed consent or parental consent for minors (if applicable).\n\nExclusion Criteria:\n\n1. Capillary malformations or congenital arteriovenous fistula.\n2. Lesions that are too close to critical structures (e.g., major blood vessels or nerves) and cannot be safely treated.\n3. Pregnancy or breastfeeding.\n4. Severe coagulopathy or significant bleeding disorders.\n5. Active infection at the treatment site.\n6. Patients with severe uncontrolled systemic disease that could interfere with treatment or recovery.\n7. Recent treatments (e.g., surgery, sclerotherapy, embolization) for the same lesion within the last 6 months.",{"count":51,"type":20},150,"INTERVENTIONAL",[54],"NA","This clinical trial aims to assess the safety and efficacy of microwave ablation in treating vascular malformations, including both venous malformations (VM) and arteriovenous malformations (AVM). Vascular malformations are abnormal clusters of blood vessels that can cause pain, swelling, and functional impairment, significantly affecting a patient's quality of life. Microwave ablation is a minimally invasive treatment that uses heat to shrink abnormal vessels, but its effectiveness and safety for these conditions need further investigation.\n\nThe trial will enroll 150 patients (100 with venous malformations and 50 with arteriovenous malformations), all of whom will undergo a single session of microwave ablation. Ultrasound guidance will be used during the procedure to precisely target the lesions, while MRI will be used for both preoperative and postoperative evaluations to assess lesion size and track changes over time.\n\nThe primary goals of the study are to determine whether microwave ablation can reduce lesion size and improve symptoms such as pain and swelling. Additionally, the study will monitor adverse events to evaluate the safety of the procedure, including any potential complications like infection, bleeding, or nerve injury.\n\nPatients will be followed for 12 months, with MRI scans taken at 1 month, 3 months, 6 months, and 12 months after the procedure to evaluate lesion shrinkage and monitor for any recurrence. Clinical symptoms will also be assessed at these time points to track improvement.\n\nThis study could provide important data on the safety and efficacy of microwave ablation, potentially offering a less invasive treatment option for patients with vascular malformations.",[57,58,26,59],"Venous Malformations","Arteriovenous Malformations","Vascular Malformations",[26,59,57,58,61],"Minimally Invasive Treatment","NOT_YET_RECRUITING","2026-02-05",{"date":65,"type":34},"2026-02-11",{"date":67,"type":20},"2026-03-01",{"date":69,"type":20},"2028-03-01",{"name":71,"class":41},"Chengdu University of Traditional Chinese Medicine",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":52,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100608153","phase-3-clinical-efficacy-and-safety-of-microwave-ablation-combined-with-huaier-granules-in-patients-with-inoperable-stage-ia-non-small-cell-lung-cancer-a-prospective-single-center-randomized-controlled-clinical-trial-100608153","NCT07197853","Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial","A Prospective, Single-Center, Randomized Controlled Trial to Evaluate the Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Stage IA Non-Small Cell Lung Cancer","HAMSTER","Inclusion Criteria\n\nAge:\n\n≥ 18 years old.\n\nDiagnosis:\n\nHistologically or cytologically confirmed IA stage non-small cell lung cancer (NSCLC) that is inoperable.\n\nECOG Performance Status:\n\n0-2 (Eastern Cooperative Oncology Group performance status).\n\nPrevious Treatment:\n\nPatients must have received no prior systemic treatment for lung cancer.\n\nInformed Consent:\n\nAbility to provide written informed consent and willingness to comply with study requirements.\n\nAdequate Organ Function:\n\nPatients must have adequate hepatic, renal, and hematologic function as evidenced by:\n\nBilirubin ≤ 1.5 × upper limit of normal (ULN)\n\nALT\u002FAST ≤ 2.5 × ULN\n\nCreatinine clearance ≥ 30 mL\u002Fmin\n\nAbsolute neutrophil count (ANC) ≥ 1,500 cells\u002FμL\n\nExclusion Criteria\n\nOther Malignancies:\n\nActive or history of other malignancies within the past 5 years, except for non-melanoma skin cancer or in situ carcinoma.\n\nSevere Concurrent Diseases:\n\nAny serious or uncontrolled medical condition such as:\n\nCardiovascular disease (e.g., recent myocardial infarction, unstable angina, or severe arrhythmia)\n\nUncontrolled diabetes or hypertension\n\nActive infections requiring systemic antibiotics or antivirals\n\nPregnancy or Breastfeeding:\n\nWomen who are pregnant, breastfeeding, or planning to become pregnant during the study.\n\nImmunosuppressive Therapy:\n\nPatients who have received immunosuppressive therapy within 30 days prior to enrollment.\n\nOther Contraindications:\n\nKnown hypersensitivity to any of the components of the treatment regimen (e.g., microwave ablation, Huai Er Granules).\n\nOther Unspecified Conditions:\n\nAny other condition or circumstances that, in the investigator's opinion, may interfere with the study or pose a risk to the patient.\n\n\\-","80 Years",{"count":82,"type":20},180,[84],"PHASE3","This prospective, single-center, randomized controlled clinical trial aims to evaluate the efficacy and safety of microwave ablation (MWA) combined with Huaier granules in patients with inoperable stage IA non-small cell lung cancer (NSCLC). A total of 180 eligible patients will be randomly assigned to receive either MWA alone or MWA combined with Huaier granules. The primary endpoint is progression-free survival (PFS) assessed by RECIST 1.1 criteria. Secondary outcomes include local progression rate (LPR), overall survival (OS), tumor markers, immune function, and quality of life. Safety will be evaluated using the CTCAE v5.0 criteria. The study seeks to determine whether the combined therapy offers improved tumor control and immune benefits over MWA alone.",[87,88,26],"Non-small Cell Lung Cancer (NSCLC)","Huaier Granules","2025-09-26",{"date":91,"type":34},"2025-09-29",{"date":93,"type":20},"2025-10-01",{"date":95,"type":20},"2028-06-30",{"name":97,"class":41},"Xin Ye",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":107,"studyType":22,"phases":4,"briefSummary":108,"conditions":109,"keywords":113,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":42},"100597110","efficacy-and-prognosis-of-microwave-ablation-treatment-for-papillary-thyroid-microcarcinoma-assessed-by-contrast-enhanced-ultrasound-combined-with-genetic-and-molecular-diagnostics-a-prospective-observational-study-100597110","NCT07054229","Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study","Inclusion Criteria:\n\n* Aged 18-70 years, gender not specified;\n* Patients with low-risk PTMC receiving initial treatment (meeting all the following conditions: single lesion with a maximum diameter ≤1cm; no cervical lymph node metastasis; no distant metastasis; no extrathyroidal extension; no family history of thyroid cancer; no history of head and neck radiation during childhood);\n* Patients who have undergone fine-needle aspiration cytology examination of thyroid nodules and 88-gene panel testing for thyroid cancer before surgery;\n* Patients voluntarily choose to undergo microwave ablation therapy or surgical resection.\n\nExclusion Criteria:\n\n* Tumor located in the isthmus of the thyroid;\n* Pathological high-risk subtypes (tall cell subtype, columnar cell subtype, diffuse sclerosing subtype, solid\u002Finsular subtype, oncocytic subtype);\n* Progressive enlargement of the cancer lesion in the short term (increase of more than 3mm within 6 months);\n* Pregnant women, lactating women;\n* Patients with severe coagulation disorders;\n* Patients with contralateral vocal cord dysfunction;\n* Patients with contraindications to ultrasound contrast agents;\n* Other conditions deemed ineligible for enrollment by the investigator.","70 Years",{"count":106,"type":20},480,"6 Months","In 2016, there were 203,000 new cases of thyroid cancer in China, ranking 7th among all malignant tumours and 4th among women, and showing a rapid growth trend. Papillary thyroid cancer (PTMC) with a diameter of ≤10 mm is the most common type of thyroid cancer, accounting for about 50% to 60% of the total number of cases. Low-risk PTMC is the most common type of thyroid cancer, with low invasiveness and good prognosis. Surgery is the treatment of choice for low-risk PTMC, but it significantly affects the quality of life of patients by affecting the function of the thyroid gland and requiring long-term medication after surgery, as well as having a high incidence of intra- and postoperative complications; there are certain impacts and limitations in the actual treatment. Microwave ablation (MWA) is a therapeutic modality emerging in recent years, which has the characteristics of easy operation, precise positioning, safety and effectiveness, small postoperative damage, fast recovery, fewer complications, and does not affect the aesthetics of the patient, which not only avoids surgical trauma and reduces the anxiety of the patient, but also better preserves the function of the thyroid gland, and its clinical application is becoming more and more widespread. In recent years, the application of microwave ablation in the treatment of PTMC has received more and more attention. Ultrasound, as a first-line examination tool, is accepted by the majority of patients because of its advantages of safety, speed, efficiency, low price and painlessness. Contrast-enhanced ultrasound (CEUS) is a new examination technique developed in recent years, which can provide richer and clearer diagnostic information than conventional ultrasound and colour Doppler ultrasound. Ultrasound contrast agents (e.g. Sonovue, Sonazoid), Sonovue with sulphur hexafluoride microbubbles as the main ingredient and Sonazoid with perfluorobutane microbubbles as the main ingredient, are non-toxic, non-radioactive, do not require allergy testing, and do not have the advantages of liver or kidney toxicity, etc., and are increasingly recognised by the public. Ultrasonography is now widely used in clinical practice as the primary modality for assessing efficacy after thyroid ablation therapy. Molecular diagnosis is one of the most important tools for preoperative diagnosis and invasiveness assessment of thyroid cancer. Common thyroid cancer gene variants include point mutations such as BRAF V600E, RAS, TP53, PIK3CA, and gene integration variants such as CCDC6-RET and ETV6-NTRK3. This project intends to assess the efficacy and prognosis of microwave ablation therapy for micropapillary thyroid cancer by ultrasonography combined with genetic molecular diagnosis, which in turn will assist in clinical treatment decisions.",[26,110,111,112],"Contrast-enhanced Ultrasound","Genetic and Molecular Diagnostics","Papillary Thyroid Microcarcinoma",[114,112,115,111],"microwave ablation","contrast-enhanced ultrasound","2025-06-26",{"date":118,"type":34},"2025-07-08",{"date":120,"type":34},"2024-01-01",{"date":122,"type":20},"2026-12-31",{"name":124,"class":41},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":52,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":42},"100562954","donafenib-as-adjuvant-therapy-following-ablation-for-recurrent-hcc-100562954","NCT06609876","Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC","Thermal Ablation Combined With Low-dose Donafinib for Early Recurrent Hepatocellular Carcinoma: a Multicenter Prospective Study","Inclusion Criteria:\n\n1. were aged 18-75 years;\n2. had recurrent HCC (RHCC) diagnosed by imaging studies, the first or the second RHCC;\n3. RHCC met the Milan criteria, namely single RHCC lesion less than 5 cm in diameter or no more than 3 tumors (each ≤3 cm in diameter);\n4. the early RHCC (recurrent time \\\u003C1 year)\n5. patients were unwilling to undergo repeat hepatectomy or liver transplantation;\n6. had well-preserved liver function, i.e., Child-Pugh class A or B, and prolonged prothrombin time≤5 s;\n7. patients had an Eastern Cooperative Oncology Group performance status score ≤1.\n8. Ability to understand the protocol and to agree to and sign a written informed consent document.\n\nExclusion Criteria:\n\n1. were under 18 years or over 75 years of age;\n2. primary HCC;\n3. recurrent HCC beyond Milan criteria;\n4. RHCC with metastasis or macrovascular tumor thrombus","75 Years",{"count":134,"type":20},108,[54],"This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.",[138,26,139,140],"Hepatocellular Carcinoma","Donafenib","Recurrent Tumor","2024-12-01",{"date":143,"type":34},"2024-12-03",{"date":145,"type":34},"2024-10-01",{"date":147,"type":20},"2028-10-01",{"name":149,"class":41},"Sun Yat-sen University",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":157,"targetDuration":4,"studyType":52,"phases":159,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":42},"100473406","microwave-ablation-simultaneously-combined-with-lenavatinib-for-recurrent-hepatocellular-carcinoma-100473406","NCT05444478","Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma","Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma: a Prospective Randomized Controlled Study","Inclusion Criteria:\n\n1. Primary HCC (BCLC 0-B), and the pathological results is hepatocellular carcinoma；\n2. recurrent HCC without any tumor related therapy；\n3. Tumor number ≤3；\n4. Tumor size ≤5cm;\n5. Good performance, KPS≥90；\n6. Age：18-75\n7. Child-Pugh A or B（score of the B level is no more than 7）\n8. Baseline laboratory examinations meet the Criteria： Leukocyte ≥3.0×109\u002FL； Blood platelet ≥75×109\u002FL； Hemoglobin ≥100g\u002FL； ALT、AST ≤ 3 x limit of normal（ULN）； Serum creatinine ≤ 1.5 x ULN； Prothrombin time \\\u003C ULN+4 s；INR \\\u003C 1.5, Albumin ≥30g\u002FL ； Total bilirubin ≤34mmol\u002FL；\n\nExclusion Criteria:\n\n1. disagreeing to receive follow-up observation and participate the clinical study;\n2. Accompanying with a history of other malignancies;\n3. Accompanying with macrovascular invasion such as portal vain tumor thrombus, hepatic vein tumor thrombus;\n4. with extrahepatic metastasis or lymph metastasis;\n5. receiving system therapy such as targeted therapy or immunotherapy;\n6. receiving local therapy such as ablation or TACE;\n7. Any of the following occurred within 12 months of the study: myocardial infarction, severe \u002F unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident (including transient ischemic attack), pulmonary embolism; ongoing arrhythmia by NCI-CTCA standard ≥ 2, prolonged QTc interval (450 ms for males, and\\> 470 ms for females;\n8. other serious acute, chronic physiological or mental disorders or abnormal laboratory examination may increase the risk of participation in study treatment or may interfere with the interpretation of study findings or whom the investigator considers not fit;",{"count":158,"type":20},274,[54],"This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC",[138,26,162,163,140],"Liver Cancer","Lenvatinib","2023-11-05",{"date":166,"type":34},"2023-11-07",{"date":168,"type":34},"2022-07-01",{"date":170,"type":20},"2027-07-01",{"name":149,"class":41}]